Cargando…
Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART)
Alterations of bone metabolism have been observed in numerous studies of HIV-infected patients. Sex steroids are known to profoundly influence bone mass and bone turnover. Hypogonadism is common in HIV-infection. Therefore, we performed a cross sectional study of 80 male HIV-infected patients withou...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351961/ https://www.ncbi.nlm.nih.gov/pubmed/19258214 http://dx.doi.org/10.1186/2047-783X-14-2-59 |
_version_ | 1782232818368118784 |
---|---|
author | Teichmann, J Lange, U Discher, T Lohmeyer, J Stracke, H Bretzel, RG |
author_facet | Teichmann, J Lange, U Discher, T Lohmeyer, J Stracke, H Bretzel, RG |
author_sort | Teichmann, J |
collection | PubMed |
description | Alterations of bone metabolism have been observed in numerous studies of HIV-infected patients. Sex steroids are known to profoundly influence bone mass and bone turnover. Hypogonadism is common in HIV-infection. Therefore, we performed a cross sectional study of 80 male HIV-infected patients without wasting syndrome, and 20 healthy male controls, in whom we analyzed urine and serum samples for both calciotropic hormones and markers of bone metabolism and of endocrine testicular function. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry both in the lumbar spine and Ward's triangle of the left hip. None of the patients received highly-active-antiretroviral-therapy (HAART). Compared to eugonadal HIV-infected patients, subjects with hypogonadism (n = 32; 40%) showed statistically significant decrease of serum osteocalcin (p < 0.05) and elevated urinary excretion of crosslinks (p < 0.05). However, we found 13 and 15, respectively, patients with osteopenia (t-score -1.0 to -2.5 SD below normal) of the lumbar spine. The dissociation between bone formation and resorption and the reduction of of BMD (p < 0.05) is stronger expressed in patients with hypogonadism. Habitual hypogonadism appears to be of additional relevance for bone metabolism of male HIV-positive patients prior to HAART. |
format | Online Article Text |
id | pubmed-3351961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33519612012-05-16 Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART) Teichmann, J Lange, U Discher, T Lohmeyer, J Stracke, H Bretzel, RG Eur J Med Res Research Alterations of bone metabolism have been observed in numerous studies of HIV-infected patients. Sex steroids are known to profoundly influence bone mass and bone turnover. Hypogonadism is common in HIV-infection. Therefore, we performed a cross sectional study of 80 male HIV-infected patients without wasting syndrome, and 20 healthy male controls, in whom we analyzed urine and serum samples for both calciotropic hormones and markers of bone metabolism and of endocrine testicular function. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry both in the lumbar spine and Ward's triangle of the left hip. None of the patients received highly-active-antiretroviral-therapy (HAART). Compared to eugonadal HIV-infected patients, subjects with hypogonadism (n = 32; 40%) showed statistically significant decrease of serum osteocalcin (p < 0.05) and elevated urinary excretion of crosslinks (p < 0.05). However, we found 13 and 15, respectively, patients with osteopenia (t-score -1.0 to -2.5 SD below normal) of the lumbar spine. The dissociation between bone formation and resorption and the reduction of of BMD (p < 0.05) is stronger expressed in patients with hypogonadism. Habitual hypogonadism appears to be of additional relevance for bone metabolism of male HIV-positive patients prior to HAART. BioMed Central 2009-02-18 /pmc/articles/PMC3351961/ /pubmed/19258214 http://dx.doi.org/10.1186/2047-783X-14-2-59 Text en Copyright ©2009 I. Holzapfel Publishers |
spellingShingle | Research Teichmann, J Lange, U Discher, T Lohmeyer, J Stracke, H Bretzel, RG Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART) |
title | Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART) |
title_full | Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART) |
title_fullStr | Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART) |
title_full_unstemmed | Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART) |
title_short | Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART) |
title_sort | bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (haart) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351961/ https://www.ncbi.nlm.nih.gov/pubmed/19258214 http://dx.doi.org/10.1186/2047-783X-14-2-59 |
work_keys_str_mv | AT teichmannj bonemineraldensityinhumanimmunodeficiencyvirus1infectedmenwithhypogonadismpriortohighlyactiveantiretroviraltherapyhaart AT langeu bonemineraldensityinhumanimmunodeficiencyvirus1infectedmenwithhypogonadismpriortohighlyactiveantiretroviraltherapyhaart AT dischert bonemineraldensityinhumanimmunodeficiencyvirus1infectedmenwithhypogonadismpriortohighlyactiveantiretroviraltherapyhaart AT lohmeyerj bonemineraldensityinhumanimmunodeficiencyvirus1infectedmenwithhypogonadismpriortohighlyactiveantiretroviraltherapyhaart AT strackeh bonemineraldensityinhumanimmunodeficiencyvirus1infectedmenwithhypogonadismpriortohighlyactiveantiretroviraltherapyhaart AT bretzelrg bonemineraldensityinhumanimmunodeficiencyvirus1infectedmenwithhypogonadismpriortohighlyactiveantiretroviraltherapyhaart |